AGENDA www.BioNJ.org 8:30 a.m. – 9:30 a.m. Registration & Networking Breakfast 9:30 a.m. – 9:45 a.m. Welcome & Opening Remarks • Debbie Hart, President & CEO, BioNJ • Grant Cale, Senior Director, Strategic Alliance & Issue Advocacy, U.S. Policy & State Government Affairs/Corporate Affairs, Bristol Myers Squibb 9:45 a.m. – 10:35 a.m. EDUCATE: AI: Using Technology for Patient Diagnostics, Clinical Research and Personalized Medicine When it comes to using artificial intelligence in healthcare, the question is no longer if it will happen — or even when. AI is here. In the next few years, AI tools will increasingly be used by pathologists, scientists and Patient care teams in treatment and clinical trial settings. AI will not replace doctors or researchers but instead be used as another diagnostic tool to augment and improve clinical care and biomedical research. Panelists: • Danielle Boyce, MPH, DPA, Caregiver; Rare Disease Advocate; Researcher; Instructor, Johns Hopkins University School of Medicine, Biomedical Informatics; and Data Science & Lead Technical Consultant, CURE Drug Repurposing Collaboratory • Jennie Lavine, Ph.D., Senior Applied Data Scientist, Koneksa Health • Andrew Pecora, M.D., FACP, CPE, Chair & CEO, Outcomes Matter Innovations & Board Member, BioNJ • Maria Picone, Caregiver, Patient Advocate & Founder and CEO, TREND Community Moderator: • Paul Howard, Ph.D., Senior Director, Public Policy, Amicus Therapeutics & Senior Advisor, Alliance for Artificial Intelligence in Healthcare 10:35 a.m. – 11:15 a.m. EDUCATE: Breakout Discussions: Biopharma & Patient Advocacy Organizations: When & How to Engage When and how should Patients, Patient Advocacy Organizations and biopharma companies work together and partner to foster medical innovation, navigate the legislative environment and ensure Patient access? Breakout Leaders: • Jayne Gershkowitz, Chief Patient Advocate, Amicus Therapeutics & Board Member, BioNJ • Gina Ross Murdoch, President & CEO, Multiple Sclerosis Association of America • Michael Parisi, Board President, CancerCare & Global Practice Lead, Medical Strategy and Communications, Lumanity 11:15 a.m. – 11:30 a.m. Networking Break 11:30 a.m. – 12:20 p.m. ENGAGE: Barriers to Care: Alternative Funding Programs Specialty drugs are often the target of cost mitigation tactics due to their high cost, despite relatively low utilization across the general population. In many cases, the only medicines available to treat complex, life limiting diseases are specialty products. Enter Alternative Funding Programs that target employer health plans with promises of reduced costs for the most expensive therapies. The result is a maze of denials and delays, leaving Patients without the treatments they need. Panelists: • Gavin Clingham, JD, Director, Public Policy, Alliance for Patient Access (AfPA) • Kim Czubaruk, JD, Associate Vice President, Policy, CancerCare • Amy Niles, MBA, Chief Advocacy & Engagement Officer, PAN Foundation Moderator: • Michele M. Oshman, Vice President, External Affairs, Biotechnology Innovation Organization 1
www.BioNJ.org AGENDA 4 2 12:20 p.m. – 1:00 p.m. ENGAGE: The Impact of IRA on Patient Access: A Roadblock to Finding Therapies and Cures Although certain provisions in the Inflation Reduction Act will bring immediate relief to Patients, including the addition of an out-of-pocket cost cap for seniors and establishment of a $35 limit on monthly insulin costs, other IRA provisions threaten to set back advancements in medical innovation and treatment access. One estimate shows price setting could result in 135 fewer new cancer drug approvals by 2039 and 551 fewer HIV/AIDS clinical trials over a similar time period. Panelist: • Lucy Ma, Director, Global Policy & Public Affairs, Pfizer • Michael Ward, MS, Vice President, Public Policy & Government Relations, Alliance for Aging Research Moderator: • Ian McLaughlin, Ph.D., Vice President, Government Affairs, BioNJ 1:00 p.m. – 1:30 p.m. Networking Lunch 1:30 p.m.- 2:00 p.m. EMPOWER: Closing Keynote by Jacqueline Smith: Two-Time Stage III Melanoma Survivor A two-time stage III melanoma survivor, Jacqueline Smith has dedicated the last decade of her life to Patient advocacy, health policy and advancing the field of cancer survivorship. During this intimate and inspirational Keynote, Jacqueline will share her cancer journey, including the need to become your own advocate, advancements through clinical trials and the impact of medical innovation. 2:00 p.m. – 2:15 p.m. Closing Remarks
SPEAKERS www.BioNJ.org 3 Danielle Boyce, MPH, DPA, Caregiver; Rare Disease Advocate; Researcher; Instructor, Johns Hopkins University School of Medicine, Biomedical Informatics; and Data Science & Lead Technical Consultant, CURE Drug Repurposing Collaboratory Dr. Boyce is a data scientist, instructor, Patient advocate and researcher. Dr. Boyce is lead technical consultant for the CURE Drug Repurposing Collaboratory (CDRC), a public-private partnership of the Critical Path Institute and the U.S. Food and Drug Administration, where she facilitates implementation of a package of resources to aid data harmonization to the OMOP common data model. She is a faculty member in the Biomedical Informatics and Data Science Section of Johns Hopkins University and serves as a scientific advisor to the Morningside Center for Innovative and Affordable Medicine at Emory University. Dr. Boyce’s work is inspired by her son, Charlie, who has a rare form of epilepsy and multiple disabilities. Grant Cale, Senior Director, Strategic Alliance and Issue Advocacy, U.S. Policy & State Government Affairs/Corporate Affairs, Bristol Myers Squibb Mr. Cale’s team builds and cultivates meaningful relationships with stakeholders’ partners to shape public policy that is mutually beneficial while supporting an environment conducive to innovation and access to innovative medicines. He started his career with Bristol Myers Squibb in 1990. In addition to leading the Strategic Alliances and Issues Advocacy team, Mr. Cale has held a number of positions with Bristol Myer Squibb; such as sales, leadership, training, operations, healthcare alliance liaison, state government operations and state government affairs. Gavin Clingham, JD, Director, Public Policy, Alliance for Patient Access Mr. Clingham is Director of Public Policy for the Alliance for Patient Access, advising on federal and state policies that impact Patient access to healthcare. With more than two decades of public policy advocacy experience, he brings a comprehensive understanding of the legislative and regulatory process, having served as Legislative Director for a senior Member of Congress. In his role, Mr. Clingham engages with federal agencies including CMS, FDA and NIH on regulatory and policy decisions. He also formulates actionable legislative strategies to advance Patient-friendly policies through the U.S. Congress and various state legislatures to ensure the healthcare provider perspective is considered as access policies are developed and implemented. Randi Bromberg, Sr. Vice President, Communications & Marketing, BioNJ Ms. Bromberg began her career in medical and scientific publishing, where she led the marketing and communications programs for some of the most prestigious medical publications. A champion for Patients, Ms. Bromberg’s role is to create and effectively execute forwardthinking strategies and campaigns which foster medical innovation, ensure Patient access and position New Jersey’s robust multi-sector life sciences ecosystem as a leading biopharma hub. She spearheads BioNJ’s work and related messaging on the importance of bringing all stakeholders together to develop Patient-centered, value-based models that will provide Patients with access to the right medicines at the right time at affordable out-of-pocket costs.
SPEAKERS www.BioNJ.org 4 Kim Czubaruk, JD, Associate Vice President, Policy, CancerCare Ms. Czubaruk is an attorney with expertise in health policy who uses her prior experience in civil litigation and disability law to help improve Patient care, coverage and outcomes. As CancerCare’s Associate Vice President of Policy, she oversees the direction of CancerCare’s advocacy efforts by developing and implementing strategic branding, cultivating alliances and advancing the organization’s national policy agenda. Ms. Czubaruk earned her Juris Doctor from George Washington University Law School and her Bachelor of Arts degree in political science from Union College. Ms. Czubaruk brings twenty-five plus years of non-profit experience and a commitment to driving meaningful Patient-centered health policy solutions. Jayne Gershkowitz, Chief Patient Advocate, Amicus Therapeutics & Board Member, BioNJ A long-time Patient advocacy professional, Ms. Gershkowitz leads Amicus’ highly regarded Global Patient & Professional Advocacy department. She founded the company’s Patient Advisory Boards program, which helps give a voice to the concerns of Patients, families and caregivers; leads Amicus’ Public Policy work to advocate for policies that satisfy unmet needs among those living with rare diseases; and initiated Healing Beyond Disease™, an Amicus initiative to further serve the rare disease community in extraordinary ways. Ms. Gershkowitz is a co-founder and Vice Chair of the Board of Professional Patient Advocates in Life Sciences (PPALS) and the former Executive Director of National Tay-Sachs & Allied Diseases Association. Debbie Hart, President & CEO, BioNJ Ms. Hart worked alongside New Jersey’s biopharmaceutical industry leaders to establish BioNJ in 1994. Dedicated to BioNJ’s mission to help our Members help Patients, Ms. Hart is recognized as a respected thought leader and influential advocate. Under Ms. Hart’s leadership, BioNJ has become the trusted voice of the life sciences industry in New Jersey – working directly with legislative leaders in both Trenton and Washington D.C. to advance the life sciences industry, foster medical innovation and Patient access, while ensuring health equity and healthcare affordability. Most recently, she was named by Governor Murphy as the Chair of the New Jersey Commission on Science, Innovation and Technology. Paul Howard, Ph.D., Senior Director, Public Policy, Amicus Therapeutics & Senior Advisor, Alliance for Artificial Intelligence in Healthcare At Amicus, Dr. Howard is responsible for ensuring consistent and appropriate implementation of overarching public policy initiatives and messages within the U.S. that help shape the legislative, reimbursement and regulatory environment for the development and marketing of products for the treatment of rare and genomic disorders. Previously, he was Senior Advisor to the Commissioner of the U.S. Food and Drug Administration on regulatory policy, strategic innovation initiatives, and promoting competition to efficiently advance public health and safety. From 2022-23, Dr. Howard served as the Co-Chair of the Regulatory Working Group and member of the Executive Committee at the Alliance for Artificial Intelligence in Healthcare.
SPEAKERS www.BioNJ.org 5 Jennie Lavine, Ph.D., Senior Applied Data Scientist, Koneksa Health Dr. Lavine’s work at Koneksa focuses on using data to discover and implement measures that matter to Patients, clinicians and regulators. She is a lead scientist in the development of Koneksa’s neuroscience toolkit, with a focus on motor, sleep and Patient-reported outcomes in Parkinson’s disease. She plays a key role in biomarker validation study design and data analysis – in Koneksa studies and with pharma partners across multiple diseases and digital data types. Dr. Lavine’s background is in infectious disease epidemiology, especially pertussis and COVID-19. She has worked with public health agencies to bring together large, diverse datasets on disease severity, infection risk and transmission patterns to enable policies that target vaccine access to minimize disease in the most vulnerable. Lucy Ma, Director, Global Policy & Public Affairs, Pfizer Ms. Ma is currently Director, Oncology Global Policy and Public Affairs at Pfizer after having served in different capacities across Corporate Affairs and Strategy and Commercial Operations. In her current role, she is responsible for leading policy and public affairs strategy development across multiple franchises, including hematology and biosimilars. Prior to joining Pfizer, Ms. Ma led a number of political and issue campaigns across the United States and served as a strategic public affairs consultant to Fortune 500 companies. She holds an MBA from Georgetown University and a dual B.A. in International Relations and Economics from the California State University, Chico. Ian McLaughlin, Ph.D., Vice President, Government Affairs, BioNJ A scientist by training, Dr. McLaughlin most recently served as a Policy Analyst in the New Jersey Assembly Majority Office, working as a Committee Aide to the Assembly Health and Aging & Senior Services Committee. During his tenure with the New Jersey Assembly Majority Office, he was responsible for analyzing legislation, department budgets and regulations; preparing briefing documents for legislative leadership; and working closely with advocates, lobbyists and stakeholders in preparing and delivering testimony before Assembly committees. At BioNJ, Dr. McLaughlin uses his scientific acumen, analytical mind and experience in working with the New Jersey Legislature to lead BioNJ’s advocacy and public policy efforts to help our Members help Patients. Gina Ross Murdoch, President & CEO, Multiple Sclerosis Association of America Ms. Murdoch serves as President and CEO of the Multiple Sclerosis Association of America (MSAA), a national non-profit organization dedicated to improving lives today for the MS community through education, direct impact and empowerment. Her career includes leadership positions with the Leukemia and Lymphoma Society, the American Diabetes Association and the National Multiple Sclerosis Society leading explosive growth initiatives and ground-breaking strategic projects. Ms. Murdoch also currently serves as Treasurer of the Multiple Sclerosis Coalition (MSC), a group of nine separate organizations dedicated to supporting the MS community. She spearheaded the first ever national Patient program, the MS Summit, engaging all nine MSC member organizations into a single initiative.
SPEAKERS www.BioNJ.org 6 Amy Niles, MBA, Chief Advocacy & Engagement Officer, PAN Foundation Ms. Niles is a knowledgeable healthcare executive with a passion for growing sustainable health organizations, advocating for Patients and building strategic partnerships to address public health needs. She leads PAN’s relationships and partnerships with the Patient advocacy and healthcare provider communities, while overseeing public policy and advocacy initiatives. Ms. Niles developed the framework for PAN’s national advocacy platform in 2013 and has been leading the initiative ever since. As a result of her leadership and proactive analysis of the legislative and regulatory environment, external stakeholders and policymakers have come to view PAN as a thought leader and “go-to” resource. Ms. Niles has helped lead successful startups and growth initiatives, including the Together Rx Access program. Michele M. Oshman, Executive Director, Council of State Bioscience Associations (CSBA) & Vice President, External Affairs, Biotechnology Innovation Organization (BIO) As the Vice President for External Affairs at BIO, Ms. Oshman leads BIO’s outreach to the Patient, consumer, multicultural and research advocacy community. As the leader of CSBA, a federation of state-based, non-profit trade organizations each governed by its own board of directors, she works to advance their mission to promote public understanding of, and advocate for public policies that support the responsible development of the bioscience industry. Ms. Oshman joined BIO in January 2020 after a successful 18-year career at Eli Lilly and Company, where she led federal advocacy outreach. She started her career as a clinical neuroscience researcher and served in multiple clinical development and corporate leadership roles. Michael Parisi, Board President, CancerCare & Global Practice Lead, Medical Strategy and Communications, Lumanity Mr. Parisi is a passionate Patient advocate, currently serving as the Board President for CancerCare and a member of the Board for LUNGevity, a non-profit organization focused on lung cancer. Mr. Parisi joined Lumanity in late 2021 through the acquisition of Guidemark Health, where he was the CEO for the past three years. He has spent his entire career working across all aspects of product development and commercialization within the oncology and rare disease marketplaces. Mr. Parisi is passionate about identifying healthcare’s biggest challenges and working collaborative to create innovative solutions. Andrew Pecora, M.D., FACP, CPE, Chair & CEO, Outcomes Matter Innovations (OMI) & Board Member, BioNJ Dr. Pecora is a national advocate for making medical practices more efficient and profitable, and at the same time, improving Patient care. Dr. Pecora is dedicated to pairing practices with artificial intelligence (AI) and health technologies to increase efficiencies, reduce costs and enable physicians to better do what they do best – heal Patients. Dr. Pecora joined OMI from Hackensack Meridian Health, where he was President, Physician Enterprise and Chief Innovation Officer. Dr. Pecora was instrumental in the creation and development of Regional Cancer Care Associates, one of the nation’s largest oncology physician networks. Dr. Pecora is also Executive Chair of COTA, a healthcare software analytics company guiding value-based care delivery for payers and providers.
SPEAKERS www.BioNJ.org 7 Maria Picone, Caregiver, Patient Advocate & Founder and CEO, TREND Community Ms. Picone is the Co-Founder and CEO of TREND Community. TREND is a digital health analytics company with a bold vision to revolutionize the world’s understanding of diseases. Ms. Picone and her husband Chris started TREND together after their daughter was born with a rare disease called Prader-Willi syndrome. TREND’s technology analyzes social media conversations to understand diseases from Patient, caregiver and care partner perspectives. These valuable insights can shed light on aspects of our health conditions that even our most qualified doctors and scientists couldn’t possibly know. Jacqueline Smith, Patient & Patient Advocate Ms. Smith is a two-time stage III melanoma survivor who is passionate about advocating for Patients, health policy and advancing cancer survivorship. She is a frequent speaker on Capitol Hill, including being a Spotlight speaker at the Biden Cancer Summit. Her cancer journey has been featured in the Washington Post, InStyle, Self Magazine, Cosmopolitan Magazine, Yahoo Health and other international publications, as well as on NPR and in documentaries. Ms. Smith serves on H. Lee Moffitt Cancer Center’s External Advisory Committee, as well as the National Cancer Institute’s (NCI) Council of Research Advocates and Human Tumor Atlas Steering Committee. Michael Ward, JD, Vice President, Public Policy & Government Relations, Alliance for Aging Research Mr. Ward leads the Alliance for Aging Research’s regulatory and legislative efforts to support research, promote Patient access and advance high-quality care. In this role, he conducts direct advocacy and strategic planning for engagement with Congressional offices, the White House and federal agencies, including the FDA, CMS and the CDC. Mr. Ward serves as a convener for multiple coalitions that elevate the Patient voice within policy spheres of influence to advance affordability, access, equity and funding for healthcare research. His work at the Alliance has also focused on advancing Patient-centered value assessment, improving methods of quality measurement and reducing out-of-pocket costs for Medicare beneficiaries.
www.BioNJ.org 108 8 THANK YOU TO OUR SPONSORS Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapies for hallucinations and delusions associated with Parkinson’s disease psychosis and for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer’s disease psychosis and neuropsychiatric symptoms in central nervous system disorders. Amicus is a global, Patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare metabolic diseases. Amicus is the Latin word for friend. This name signifies our collaborative approach to developing medicines by incorporating the Patient perspective every step of the way. By championing mission-dedication, innovation, performance and integrity, we are united by our passion for making a difference and committed to pushing ideas as far and as fast as possible. The Biotechnology Innovation Organization (BIO) is the world’s largest non-profit trade association for biotechnology. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental solutions. BIO supports the industry as a powerful advocate domestically and abroad; by providing BIO Business Solutions, the world’s largest cost savings program for the life sciences community; by hosting a suite of renowned business development events, including the BIO International Convention; and by reporting critical industry news and policy updates in Good Day BIO, Bio.News, and the I Am BIO podcast. Learn more at bio.org. At Bristol Myers Squibb, we are driven by a single vision: transforming Patients’ lives through science. Throughout our 164-year history, we have been focused on discovering, developing and delivering innovative medicines that help Patients around the world prevail over serious diseases. We seek breakthroughs – innovations that have the power to bring hope for Patients with life-altering conditions like cancer and diseases of the heart, immune system and blood. Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using unique, cutting-edge antibody technology, Genmab’s world-class discovery and development teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases, including cancer and autoimmune disorders. As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of Patients who are in urgent need of new treatment options.
www.BioNJ.org ATTENDEE LIST First Name Last Name Title Company Chinenye Agim GPA Bristol Myers Squib Stacey Alphas Associate Director, Patient Engagement Bristol Myers Squib Matthew Alsante Senior Director, Patient Advocacy Bristol Myers Squib Jeffrey Anders Director, Advocacy Color of Crohn's and Chronic Illness Deena Andreola Director, Therapeutic Policy & Advocacy Takeda Dora Arias Founder & Executive Director Curemonos Brian Arnold Vice President, Development Operations Insmed Incorporated Laura Atwell Vice President, Philanthropy Crossroads4Hope Andy Bala Founder & CEO Delphine Diagnostics Inc Bob Bartocci Director Bristol Myers Squib Claire Bassetti Communication and Patient Engagement Manager Critical Path Institute-CURE Drug Repurposing Collaboratory Nancy Bayerlein Senior Director, Patient Engagement and Support Mitsubishi Tanabe Pharma America Josh Bengal Director, Government Relations & Staff Counsel Medical Society of New Jersey Adi Ben-Guy Research Associate CMPI Carly Boos Executive Director CLL Society Angie Botto-van Bemden Global Patient Ambassador University of Maryland PATIENTS Program Danielle Boyce Researcher John Hopkins University Grant Cale Alliance Development Bristol Myers Squib Matthew Camarda Public Relations & Advocacy New Jersey Association of Mental Health and Addiction Agencies Stephanie Chapelliquen State Lead Ambassador American Cancer Society Cancer Action Network Alana ClemensSaliba Executive Director, Patient Advocacy Insmed Incorporated Gavin Clingham Director of Public Policy Alliance for Patient Access Gail Cohen C-Suite Corporate Affairs & IR Advisor GBC Patricia Cornet Senior Director, Patient Advocacy Oncology Bristol Myers Squib George Coutros Director, State Government Affairs Sanofi Kim Czubaruk Associate Vice President, Policy CancerCare Roslyn Daniels President & Founder Black Health Matters Vincent Del Gaizo Director, Partnerships & Patient Engagement Childhood Arthritis and Rheumatology Research Alliance Maya Doyle Associate Professor/Social Work Quinnipiac University Debbie Drell Senior Director, Membership National Organization for Rare Disorders Martina Flammer Chief Medical Officer Insmed Incorporated Italia Folleco Patient & Family Advisor Council Chair JoeDiMaggio Children’s Hospital Cecilia Fong Director, Marketing Research Genmab Christina Ftikas Board Member Don’t Forget Morgan Foundation - BPAN Catherine Gamble Senior Manager Bristol Myers Squib 9
www.BioNJ.org 10 ATTENDEE LIST First Name Last Name Title Company Lin Gao Senior Director, Medical Writing & TT&D Insmed Incorporated Patrick Gee Healthcare Consultant iAdvocate Jayne Gershkowitz Chief Patient Advocate Amicus Therapeutics Karin Gillespie Director, Alliance Development Novo Nordisk Robert Goldberg Vice President CMPI Awara Gomis Senior Manager, Regional Clinical Operations Vendor Ops Bristol Myers Squib Jasmine Greenamyer Executive Director, Global Patient Advocacy Bristol Myers Squib Leslie Greenfield Executive Director New Jersey Rett Syndrome Association Liza Gundell CEO Family Resource Network/Epilepsy Services of NJ Maureen Hart Director, Patient Advocacy & Policy Creyon Bio Scott Harwood Director, Corporate Outreach & Strategic Alliance CheckRare Ethan Hasbrouck Director, State Government Affairs Bristol Myers Squib Juliet Herbert Director, Patient Advocacy, Cardiovascular Bristol Myers Squib Paul Howard Senior Director, Public Policy Amicus Therapeutics Candace Howell Director, Global Patient Advocacy Bristol Myers Squib Tracey Iraca Executive Director MDS Foundation Ina Islam Patient Advocacy & Communications Kyowa Kirin Sho Islam Division Head, Life Sciences & Food Innovation Office of Business Engagement, Middlesex County Alissa Jaffe Nagler Consultant AJN Advisors Claire Judkins Patient Advocacy & Industry Relations Senior Liaison Acadia Pharmaceuticals Ann Kent Director, Corporate & Foundation Relations Crossroads4Hope, A Network of Cancer Support Shawn Keogan Patient Advocacy & Professional Relations Genmab Jennie Lavine Senior Applied Data Scientist Koneksa Health Wendy Lazarus Principal WML Public Affairs Valarie Leishman Lead Patient & Professional Services Lumanity Wendy Lewis Care Coordinator UCB Alyssa Lovill Executive Director, Regional Teams Epilepsy Foundation of America Sarah Lucas Eaton Patient Strategy Director Lumanity James Lynch CEO Nano Pharmaceuticals Will Ma Founder & CEO HopeAI Lucy Ma Director, Global Policy & Public Affairs Pfizer Kathy Machuzak Director, Patient Advocacy Travere Therapeutics Meredith Masin Blount Executive Director New Jersey Association of Mental Health and Addiction Agencies Michael Mattoon Vice President, Government Affairs Acadia Pharmaceuticals Michele McCourt Executive Director CancerCare Co-Payment Assistance Foundation Keri McDonough Head, Patient Voice Consortium Syneos Health
www.BioNJ.org ATTENDEE LIST First Name Last Name Title Company Emily Michael Director, Federal Government Relations Biotechnology Innovation Organization Robert Millar President EmphyCorp Pharmaceutical Ashley Moncrief Director, Patient Care MDS Foundation Linda Montgomery Client Advocate Hypertrophic Cardiomyopathy Association Elena Morgan Assistant Director Hypertrophic Cardiomyopathy Association Miryah Morris Director Bristol Myers Squib Shauna Moses Vice President, Public Affairs & Member Services New Jersey Association of Mental Health and Addiction Agencies Terris Moss Associate Director, EOE Bristol Myers Squib Paul Muniz Senior Vice President, Community Engagement Family Resource Network/Epilepsy Services of NJ Paul Muniz Senior Vice President, Community Engagement Family Resource Network/Epilepsy Services of NJ Gina Murdoch President & CEO Multiple Sclerosis Association of America Siddhartha Nanda Assistant Scientist Bristol Myers Squib Shrinidhi Navale Quality Assurance Amy Niles Chief Advocacy & Engagement Officer Patient Access Network (PAN) Foundation Anne OBrien Partnership Solutions Black Health Matters Michele Oshman Vice President, External Affairs Biotechnology Innovation Organization Michael Parisi Global Practice Lead Lumanity Liz Parlett Butcher Associate Director, Patient Advocacy Kyowa Kirin Fernando Parra Chong Strategic Partnerships Specialist CLL Society Neha Patel Medical Communications Expert (Patient Education) Andrew Pecora CEO and Executive Chairman Outcomes Matter Innovations Josee Pelletier Director Bristol Myers Squib Patricia Phillips Executive Director New Jersey Center for Tourette Syndrome & Associated Disorders Monique Phillips PBRG Lead Bristol Myers Squib MarÃa Decavi Pissoni Founder FUSAENM (Fundación Salteña de enfermedades neuromusculares) Ariel Pissoni Treasurer FUSAENM (Fundación Salteña de enfermedades neuromusculares) Heather Pongonis Project Manager Bristol Myers Squib Matthew Prol Director, Corporate Development Sepsis Alliance MARIE RECINE Freelance Medical Writer/Patient Advocate Medical & Scientific Communications Kevin Rigby Founder Rigby Consulting Patricia Roselle Global Head, Patient Stakeholder Engagement Sanofi Julie Russo Volunteer Coordinator Hypertrophic Cardiomyopathy Association Malisa Rust Patient Engagement Liaison PTC Therapeutics 11
www.BioNJ.org 12 ATTENDEE LIST First Name Last Name Title Company June Sanson Senior Director, Patient Advocacy & Industry Relation Acadia Pharmaceuticals Navaneetha Santhanam Patient Engagement & Recruitment Lead Bristol Myers Squib Monica Santora Intern AbbVie Gerard Saydah Board of Directors New Jersey Rett Syndrome Association Katherine Schaible Senior Director, Program & Impact Crossroads4Hope, A Network of Cancer Support Lisa Schill Partner GnL Partners Fatima Scipione Vice President, Global Patient Affairs Blueprint Medicines Sonia Sequeira CEO VITRUVIAE Amanda Sergison-Main Associate Director, Patient Engagement Lumanity Glenda Sexauer WomenHeart Champion WomenHeart Champion John Shea Director Merck & Co. Jacqueline Smith Director, Grassroots Advocacy & State Government Affairs Vertex Pharmaceuticals Amanda Sowinski Associate Director, Patient & Professional Advocacy Amicus Therapeutics Richard Standifer Director Bristol Myers Squib Willis Steele GPA Bristol Myers Squib Susan Stein Executive Director, Patient Advocacy Agenus Leslie Stein Lloyd Health Policy & Advocacy Director Johnson & Johnson Narasimha Priya Sundarajan Senior Specialist, Quality Compliance & Regulatory Catalent Pharma Solutions Ranjit Suresh Senior Director, Business Development OncoBay Clinical Amy Sutton CEO Crossroads4Hope, A Network of Cancer Support Julia Terrell Director, Community Relations The Sturge-Weber Foundation Kate Tighe Head, US Public Affairs & Patient Advocacy Sanofi Dawn Van Wagenen Executive Assistant to the CMO Insmed Incorporated Achilles Vergis Associate Director, Alliance Management, Business Development Kyowa Kirin Colleen Vineer Senior Project Manager, Patient Advocacy Agios Pharmaceuticals Valerie Volpe Public Policy & Government Affairs Regeneron Pharmaceuticals Michael Ward Vice President, Public Policy, Government Relation Alliance for Aging Research MarlaJan Wexler CEO & President Luck Fupus Meredith Wilson Senior Vice President, Advocacy Syneos Health Debbie Yobs CEO CJD Foundation Melissa Young Associate Vice President, Mission Delivery Multiple Sclerosis Association of America